基石藥業(02616.HK)與多特生物簽訂合作協議
基石藥業(02616.HK)公布,與專注開發下一代抗體療法的生物科技公司多特生物簽訂合作協議,為其首個入駐蘇州的基石藥業全球研發中心及產業化基地的合作項目,基石藥業將根據期望達到的作用機制主導設計靶點組合,多特生物將主導分子的設計和構建。
公司表示,多特生物專有的DotBody技術平台基於模塊化概念設計,擁有預先研發的具有特定功能的抗體
模塊。該合作將為基石藥業管線2.0戰略提供臨床前候選藥物,進一步推動藥物研發和源頭創新。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.